CZ20004896A3 - Pharmaceutical preparation containing inhibitor COX-2 and inhibitor iNOS - Google Patents
Pharmaceutical preparation containing inhibitor COX-2 and inhibitor iNOS Download PDFInfo
- Publication number
- CZ20004896A3 CZ20004896A3 CZ20004896A CZ20004896A CZ20004896A3 CZ 20004896 A3 CZ20004896 A3 CZ 20004896A3 CZ 20004896 A CZ20004896 A CZ 20004896A CZ 20004896 A CZ20004896 A CZ 20004896A CZ 20004896 A3 CZ20004896 A3 CZ 20004896A3
- Authority
- CZ
- Czechia
- Prior art keywords
- quinazoline
- piperidine
- amine
- spiro
- amino
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 32
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 title description 35
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 title 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 title 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 11
- -1 nitro, hydroxymethyl Chemical group 0.000 claims description 107
- 239000000203 mixture Substances 0.000 claims description 37
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 26
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 25
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 22
- 125000004432 carbon atom Chemical group C* 0.000 claims description 21
- 229940111134 coxibs Drugs 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- 229910052717 sulfur Chemical group 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 17
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 15
- 239000001301 oxygen Substances 0.000 claims description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- 125000005842 heteroatom Chemical group 0.000 claims description 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 11
- 239000011593 sulfur Chemical group 0.000 claims description 11
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 238000011321 prophylaxis Methods 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 125000004434 sulfur atom Chemical group 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 229960000590 celecoxib Drugs 0.000 claims description 6
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 125000004414 alkyl thio group Chemical group 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 claims description 2
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 229950005722 flosulide Drugs 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- 229960001929 meloxicam Drugs 0.000 claims description 2
- CXJONBHNIJFARE-UHFFFAOYSA-N n-[6-(2,4-difluorophenoxy)-1-oxo-2,3-dihydroinden-5-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCC(=O)C=2C=C1OC1=CC=C(F)C=C1F CXJONBHNIJFARE-UHFFFAOYSA-N 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000005493 quinolyl group Chemical group 0.000 claims description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- MIMJSJSRRDZIPW-UHFFFAOYSA-N tilmacoxib Chemical compound C=1C=C(S(N)(=O)=O)C(F)=CC=1C=1OC(C)=NC=1C1CCCCC1 MIMJSJSRRDZIPW-UHFFFAOYSA-N 0.000 claims description 2
- 125000003003 spiro group Chemical group 0.000 claims 67
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims 37
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 3
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 claims 3
- 150000001412 amines Chemical class 0.000 claims 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- JLAKCHGEEBPDQI-UHFFFAOYSA-N 4-(4-fluorobenzyl)piperidine Chemical compound C1=CC(F)=CC=C1CC1CCNCC1 JLAKCHGEEBPDQI-UHFFFAOYSA-N 0.000 claims 2
- 125000002672 4-bromobenzoyl group Chemical group BrC1=CC=C(C(=O)*)C=C1 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 claims 2
- KOCBGBJUDZNSJE-UHFFFAOYSA-N (4-amino-5,7-difluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-thiophen-2-ylmethanone Chemical compound N1C2=CC(F)=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=CS1 KOCBGBJUDZNSJE-UHFFFAOYSA-N 0.000 claims 1
- NSMOJXCJICOFKS-UHFFFAOYSA-N (4-amino-5,8-difluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(6-chloropyridin-3-yl)methanone Chemical compound N1C2=C(F)C=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(Cl)N=C1 NSMOJXCJICOFKS-UHFFFAOYSA-N 0.000 claims 1
- KFHRZNJUQDYBJY-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(1,2-oxazol-3-yl)methanone Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C=1C=CON=1 KFHRZNJUQDYBJY-UHFFFAOYSA-N 0.000 claims 1
- LPHXOGYMVXBMGV-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(4-bromothiophen-2-yl)methanone Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC(Br)=CS1 LPHXOGYMVXBMGV-UHFFFAOYSA-N 0.000 claims 1
- ISYQOHGPHWEVDP-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(5-chlorothiophen-2-yl)methanone Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(Cl)S1 ISYQOHGPHWEVDP-UHFFFAOYSA-N 0.000 claims 1
- SJSUYOCGLNUZHL-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(5-methylpyrazin-2-yl)methanone Chemical compound C1=NC(C)=CN=C1C(=O)N1CCC2(N=C(N)C3=C(F)C=CC=C3N2)CC1 SJSUYOCGLNUZHL-UHFFFAOYSA-N 0.000 claims 1
- IZTDKOVHEGYKPL-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(6-chloropyridin-3-yl)methanone Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(Cl)N=C1 IZTDKOVHEGYKPL-UHFFFAOYSA-N 0.000 claims 1
- MPTWCHUKDCSDPV-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(furan-2-yl)methanone Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=CO1 MPTWCHUKDCSDPV-UHFFFAOYSA-N 0.000 claims 1
- XGEBICJDODHDSM-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(thiadiazol-4-yl)methanone Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C1=CSN=N1 XGEBICJDODHDSM-UHFFFAOYSA-N 0.000 claims 1
- ABHMXNAQNFTILP-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-imidazol-1-ylmethanone Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)N1C=CN=C1 ABHMXNAQNFTILP-UHFFFAOYSA-N 0.000 claims 1
- WZEHIPZGALGBOI-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-pyrrolidin-1-ylmethanone Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)N1CCCC1 WZEHIPZGALGBOI-UHFFFAOYSA-N 0.000 claims 1
- FHRCQQIVIJAXMW-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-thiophen-3-ylmethanone Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C=1C=CSC=1 FHRCQQIVIJAXMW-UHFFFAOYSA-N 0.000 claims 1
- YOGMHFXUEGAVGP-UHFFFAOYSA-N (4-amino-5-hydroxyspiro[1H-quinazoline-2,4'-piperidine]-1'-yl)-(4-bromophenyl)methanone Chemical compound BrC1=CC=C(C(=O)N2CCC3(CC2)NC2=CC=CC(=C2C(=N3)N)O)C=C1 YOGMHFXUEGAVGP-UHFFFAOYSA-N 0.000 claims 1
- HUGDORSEMMDVLL-UHFFFAOYSA-N (4-aminophenyl)-(4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)methanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(N)C=C1 HUGDORSEMMDVLL-UHFFFAOYSA-N 0.000 claims 1
- AGPKOMWNUUEILQ-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(1,3-thiazol-2-yl)methanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=NC=CS1 AGPKOMWNUUEILQ-UHFFFAOYSA-N 0.000 claims 1
- YTFXUYQLAYFSDK-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(2-nitrophenyl)methanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=CC=C1[N+]([O-])=O YTFXUYQLAYFSDK-UHFFFAOYSA-N 0.000 claims 1
- ZHMUHIIKTOAYBJ-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(4-ethylphenyl)methanone Chemical compound C1=CC(CC)=CC=C1C(=O)N1CCC2(N=C(N)C3=CC=CC=C3N2)CC1 ZHMUHIIKTOAYBJ-UHFFFAOYSA-N 0.000 claims 1
- ZYTYCDYFRYWVRC-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(4-fluorophenyl)methanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(F)C=C1 ZYTYCDYFRYWVRC-UHFFFAOYSA-N 0.000 claims 1
- FOHCTSUZLZRUHD-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-[4-(trifluoromethyl)phenyl]methanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(C(F)(F)F)C=C1 FOHCTSUZLZRUHD-UHFFFAOYSA-N 0.000 claims 1
- YCPVARZUSFKJFC-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-thiophen-2-ylmethanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=CS1 YCPVARZUSFKJFC-UHFFFAOYSA-N 0.000 claims 1
- BANAKXZRCPMACJ-UHFFFAOYSA-N 1'-(1,3-thiazol-2-yl)spiro[1h-quinazoline-2,4'-piperidine]-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C1=NC=CS1 BANAKXZRCPMACJ-UHFFFAOYSA-N 0.000 claims 1
- LIWDTGMJUGTXEP-UHFFFAOYSA-N 1,2-dihydroquinazolin-4-amine Chemical compound C1=CC=C2C(N)=NCNC2=C1 LIWDTGMJUGTXEP-UHFFFAOYSA-N 0.000 claims 1
- OGXGDEWNXVPOSL-UHFFFAOYSA-N 1-(4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-4-phenoxybutan-1-one Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)CCCOC1=CC=CC=C1 OGXGDEWNXVPOSL-UHFFFAOYSA-N 0.000 claims 1
- ZCULUGBJSMGCDG-UHFFFAOYSA-N 1-methyl-2-phenyl-2h-quinazolin-4-amine Chemical compound N1=C(N)C2=CC=CC=C2N(C)C1C1=CC=CC=C1 ZCULUGBJSMGCDG-UHFFFAOYSA-N 0.000 claims 1
- GOAQIFIXXGXKFF-UHFFFAOYSA-N 2,2-dimethyl-1h-quinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC(C)(C)NC2=C1 GOAQIFIXXGXKFF-UHFFFAOYSA-N 0.000 claims 1
- OESYASHKFVCSTL-UHFFFAOYSA-N 2-(1,3-thiazol-2-yl)-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1C1=NC=CS1 OESYASHKFVCSTL-UHFFFAOYSA-N 0.000 claims 1
- WPMXZRLXEGVIHU-UHFFFAOYSA-N 2-(1h-imidazol-2-yl)-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1C1=NC=CN1 WPMXZRLXEGVIHU-UHFFFAOYSA-N 0.000 claims 1
- OSFDRCPUKQFYBL-UHFFFAOYSA-N 2-(2-aminoethyl)-1,2-dihydroquinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC(CCN)NC2=C1 OSFDRCPUKQFYBL-UHFFFAOYSA-N 0.000 claims 1
- SRZVHVKEKUVWKE-UHFFFAOYSA-N 2-(2-nitrophenyl)-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1C1=CC=CC=C1[N+]([O-])=O SRZVHVKEKUVWKE-UHFFFAOYSA-N 0.000 claims 1
- PZFBPUAOCMMRLZ-UHFFFAOYSA-N 2-(2-trimethylsilylethynyl)-1,2-dihydroquinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC(C#C[Si](C)(C)C)NC2=C1 PZFBPUAOCMMRLZ-UHFFFAOYSA-N 0.000 claims 1
- DRBTXTOYZCLBJI-UHFFFAOYSA-N 2-(3-aminopropyl)-1,2-dihydroquinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC(CCCN)NC2=C1 DRBTXTOYZCLBJI-UHFFFAOYSA-N 0.000 claims 1
- WKAUNVBOSOJUSS-UHFFFAOYSA-N 2-(4-amino-5-fluoro-1,2-dihydroquinazolin-2-yl)phenol Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1C1=CC=CC=C1O WKAUNVBOSOJUSS-UHFFFAOYSA-N 0.000 claims 1
- QFSLLBYFMDJKDY-UHFFFAOYSA-N 2-(4-nitrophenyl)-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1C1=CC=C([N+]([O-])=O)C=C1 QFSLLBYFMDJKDY-UHFFFAOYSA-N 0.000 claims 1
- HLWCINSTSGDTIB-UHFFFAOYSA-N 2-(5-nitrothiophen-2-yl)-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1C1=CC=C([N+]([O-])=O)S1 HLWCINSTSGDTIB-UHFFFAOYSA-N 0.000 claims 1
- RIOVUWRMOKFDQS-UHFFFAOYSA-N 2-(furan-2-yl)-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1C1=CC=CO1 RIOVUWRMOKFDQS-UHFFFAOYSA-N 0.000 claims 1
- KCGIUYAUVHLJJL-UHFFFAOYSA-N 2-[2-(2-aminoethyl)phenyl]-1,2-dihydroquinazolin-4-amine Chemical compound NCCC1=CC=CC=C1C1N=C(N)C2=CC=CC=C2N1 KCGIUYAUVHLJJL-UHFFFAOYSA-N 0.000 claims 1
- PFKHXJPYRVMZLW-UHFFFAOYSA-N 2-[4-(dimethylamino)phenyl]-1,2-dihydroquinazolin-4-amine Chemical compound C1=CC(N(C)C)=CC=C1C1N=C(N)C2=CC=CC=C2N1 PFKHXJPYRVMZLW-UHFFFAOYSA-N 0.000 claims 1
- GTEZSHJBMRWRIG-UHFFFAOYSA-N 2-amino-3-[4-(naphthalene-2-carbonyloxy)phenyl]propanoic acid Chemical group C1=CC(CC(N)C(O)=O)=CC=C1OC(=O)C1=CC=C(C=CC=C2)C2=C1 GTEZSHJBMRWRIG-UHFFFAOYSA-N 0.000 claims 1
- UIIANCNAHLNGKW-UHFFFAOYSA-N 2-anthracen-9-yl-1,2-dihydroquinazolin-4-amine Chemical compound C1=CC=C2C(C3N=C(C4=CC=CC=C4N3)N)=C(C=CC=C3)C3=CC2=C1 UIIANCNAHLNGKW-UHFFFAOYSA-N 0.000 claims 1
- YQSLFNIIJBAELO-UHFFFAOYSA-N 2-cyclobutyl-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1C1CCC1 YQSLFNIIJBAELO-UHFFFAOYSA-N 0.000 claims 1
- TWDKMKHCHFFGDT-UHFFFAOYSA-N 2-cyclobutyl-5-fluoro-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1C1CCC1 TWDKMKHCHFFGDT-UHFFFAOYSA-N 0.000 claims 1
- CODFUQOUEHCCNF-UHFFFAOYSA-N 2-cyclopentyl-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1C1CCCC1 CODFUQOUEHCCNF-UHFFFAOYSA-N 0.000 claims 1
- MXQUJZRTIGEIOF-UHFFFAOYSA-N 2-cyclopropyl-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1C1CC1 MXQUJZRTIGEIOF-UHFFFAOYSA-N 0.000 claims 1
- YFDYGSPBBLYHLX-UHFFFAOYSA-N 2-cyclopropyl-1-methyl-2h-quinazolin-4-amine Chemical compound N1=C(N)C2=CC=CC=C2N(C)C1C1CC1 YFDYGSPBBLYHLX-UHFFFAOYSA-N 0.000 claims 1
- MFRCBOKLESMGRI-UHFFFAOYSA-N 2-ethyl-1,2-dihydroquinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC(CC)NC2=C1 MFRCBOKLESMGRI-UHFFFAOYSA-N 0.000 claims 1
- REYBEBUFZZALFV-UHFFFAOYSA-N 2-ethyl-2-methyl-1h-quinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC(CC)(C)NC2=C1 REYBEBUFZZALFV-UHFFFAOYSA-N 0.000 claims 1
- KKIKPJKOGYZZHP-UHFFFAOYSA-N 2-ethynyl-1,2-dihydroquinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC(C#C)NC2=C1 KKIKPJKOGYZZHP-UHFFFAOYSA-N 0.000 claims 1
- BFASSLCZFJPKRD-UHFFFAOYSA-N 2-methyl-1,2-dihydroquinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC(C)NC2=C1 BFASSLCZFJPKRD-UHFFFAOYSA-N 0.000 claims 1
- YVXJSSLNOVOYBG-UHFFFAOYSA-N 2-methyl-2-phenyl-1h-quinazolin-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1(C)C1=CC=CC=C1 YVXJSSLNOVOYBG-UHFFFAOYSA-N 0.000 claims 1
- VRHGJUOMOHIJKK-UHFFFAOYSA-N 2-phenyl-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1C1=CC=CC=C1 VRHGJUOMOHIJKK-UHFFFAOYSA-N 0.000 claims 1
- HRFIDKBTEAWKLR-UHFFFAOYSA-N 2-pyridin-4-yl-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1C1=CC=NC=C1 HRFIDKBTEAWKLR-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- YXOPNVUMAUDDSS-UHFFFAOYSA-N 2-thiophen-2-yl-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1C1=CC=CS1 YXOPNVUMAUDDSS-UHFFFAOYSA-N 0.000 claims 1
- FBZPVUKOYWWJBN-UHFFFAOYSA-N 3-(4-amino-5-fluoro-1,2-dihydroquinazolin-2-yl)phenol Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1C1=CC=CC(O)=C1 FBZPVUKOYWWJBN-UHFFFAOYSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- JREYTKUJENPMHF-UHFFFAOYSA-N 4-(4-amino-1,2-dihydroquinazolin-2-yl)benzonitrile Chemical compound N1C2=CC=CC=C2C(N)=NC1C1=CC=C(C#N)C=C1 JREYTKUJENPMHF-UHFFFAOYSA-N 0.000 claims 1
- SJUUAYNNEIVONX-UHFFFAOYSA-N 4-(4-amino-5-fluoro-1,2-dihydroquinazolin-2-yl)phenol Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1C1=CC=C(O)C=C1 SJUUAYNNEIVONX-UHFFFAOYSA-N 0.000 claims 1
- CKXPAAJCRIZEOC-UHFFFAOYSA-N 4-(4-amino-5-hydroxyspiro[1H-quinazoline-2,4'-piperidine]-1'-carbonyl)benzonitrile Chemical compound C(#N)C1=CC=C(C(=O)N2CCC3(NC4=CC=CC(=C4C(=N3)N)O)CC2)C=C1 CKXPAAJCRIZEOC-UHFFFAOYSA-N 0.000 claims 1
- 125000001999 4-Methoxybenzoyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C(*)=O 0.000 claims 1
- NTSNKFYZLVZBHJ-UHFFFAOYSA-N 5'-fluoro-1'-[2-(4-methyl-1,3-thiazol-5-yl)ethyl]spiro[piperidine-4,2'-quinazoline]-4'-amine Chemical compound CC=1N=CSC=1CCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 NTSNKFYZLVZBHJ-UHFFFAOYSA-N 0.000 claims 1
- ZBZXORNPMDSVBO-UHFFFAOYSA-N 5-chloro-2-(furan-2-yl)-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC(Cl)=C2C(N)=NC1C1=CC=CO1 ZBZXORNPMDSVBO-UHFFFAOYSA-N 0.000 claims 1
- KZMMWKJKRXYXRH-UHFFFAOYSA-N 5-chloro-2-thiophen-2-yl-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC(Cl)=C2C(N)=NC1C1=CC=CS1 KZMMWKJKRXYXRH-UHFFFAOYSA-N 0.000 claims 1
- NGFFAUZBTWFKRY-UHFFFAOYSA-N 5-fluoro-2-(1,3-thiazol-2-yl)-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1C1=NC=CS1 NGFFAUZBTWFKRY-UHFFFAOYSA-N 0.000 claims 1
- AKOSZLBIPKPADG-UHFFFAOYSA-N 5-fluoro-2-(4-fluorophenyl)-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1C1=CC=C(F)C=C1 AKOSZLBIPKPADG-UHFFFAOYSA-N 0.000 claims 1
- ADVXVBOVHBALNY-UHFFFAOYSA-N 5-fluoro-2-(4-methoxyphenyl)-1,2-dihydroquinazolin-4-amine Chemical compound C1=CC(OC)=CC=C1C1N=C(N)C2=C(F)C=CC=C2N1 ADVXVBOVHBALNY-UHFFFAOYSA-N 0.000 claims 1
- UYXRIQUZSCKEBY-UHFFFAOYSA-N 5-fluoro-2-(4-methylsulfanylphenyl)-1,2-dihydroquinazolin-4-amine Chemical compound C1=CC(SC)=CC=C1C1N=C(N)C2=C(F)C=CC=C2N1 UYXRIQUZSCKEBY-UHFFFAOYSA-N 0.000 claims 1
- ADRXNSWTWMXBHN-UHFFFAOYSA-N 5-fluoro-2-(furan-2-yl)-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1C1=CC=CO1 ADRXNSWTWMXBHN-UHFFFAOYSA-N 0.000 claims 1
- PIVPSBNKQBZPLC-UHFFFAOYSA-N 5-fluoro-2-(furan-2-yl)-2-methyl-1h-quinazolin-4-amine Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(C)C1=CC=CO1 PIVPSBNKQBZPLC-UHFFFAOYSA-N 0.000 claims 1
- WHZFSGZHOACEEC-UHFFFAOYSA-N 5-fluoro-2-[2-(trifluoromethyl)phenyl]-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1C1=CC=CC=C1C(F)(F)F WHZFSGZHOACEEC-UHFFFAOYSA-N 0.000 claims 1
- IABLTGUVVWICLB-UHFFFAOYSA-N 5-fluoro-2-[4-(trifluoromethyl)phenyl]-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1C1=CC=C(C(F)(F)F)C=C1 IABLTGUVVWICLB-UHFFFAOYSA-N 0.000 claims 1
- QFNLYCUBYXJYKQ-UHFFFAOYSA-N 5-fluoro-2-phenyl-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1C1=CC=CC=C1 QFNLYCUBYXJYKQ-UHFFFAOYSA-N 0.000 claims 1
- VAKMJMYAYACJOE-UHFFFAOYSA-N 5-fluoro-2-propan-2-yl-1,2-dihydroquinazolin-4-amine Chemical compound C1=CC(F)=C2C(N)=NC(C(C)C)NC2=C1 VAKMJMYAYACJOE-UHFFFAOYSA-N 0.000 claims 1
- OGKZGPSVQKXXOY-UHFFFAOYSA-N 5-fluoro-2-thiophen-2-yl-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1C1=CC=CS1 OGKZGPSVQKXXOY-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- VHWJKNADPXGAPZ-UHFFFAOYSA-N C1CN(CCC12N=C(C3=C(N2C=N)C=CC=C3F)N)C4=CC=CS4 Chemical compound C1CN(CCC12N=C(C3=C(N2C=N)C=CC=C3F)N)C4=CC=CS4 VHWJKNADPXGAPZ-UHFFFAOYSA-N 0.000 claims 1
- RUOQPBAHDHCUSJ-UHFFFAOYSA-N CC1=CC=C(C=C1)C(=O)N2CCC3(CC2)NC4=CC=CC=C4C=N3 Chemical compound CC1=CC=C(C=C1)C(=O)N2CCC3(CC2)NC4=CC=CC=C4C=N3 RUOQPBAHDHCUSJ-UHFFFAOYSA-N 0.000 claims 1
- PCTJAEQLKCMDJX-UHFFFAOYSA-N ClC1=CC=C(OCCN2C3(N=C(C4=C(C=CC=C24)F)N)CCNCC3)C=C1 Chemical compound ClC1=CC=C(OCCN2C3(N=C(C4=C(C=CC=C24)F)N)CCNCC3)C=C1 PCTJAEQLKCMDJX-UHFFFAOYSA-N 0.000 claims 1
- ABUUEHASPZQEEC-UHFFFAOYSA-N N1=C(C=CC=C1)CCCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 Chemical compound N1=C(C=CC=C1)CCCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 ABUUEHASPZQEEC-UHFFFAOYSA-N 0.000 claims 1
- UIFMUEINMFLQOH-UHFFFAOYSA-N N1=C(C=CC=C1)SCCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 Chemical compound N1=C(C=CC=C1)SCCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 UIFMUEINMFLQOH-UHFFFAOYSA-N 0.000 claims 1
- WXGRPMHGVVXFSS-UHFFFAOYSA-N [2-(4-amino-1,2-dihydroquinazolin-2-yl)phenyl]methanol Chemical compound N1C2=CC=CC=C2C(N)=NC1C1=CC=CC=C1CO WXGRPMHGVVXFSS-UHFFFAOYSA-N 0.000 claims 1
- APYSBADMUOHVGZ-UHFFFAOYSA-N benzyl 4-amino-5-fluorospiro[1h-quinazoline-2,3'-azetidine]-1'-carboxylate Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(C1)CN1C(=O)OCC1=CC=CC=C1 APYSBADMUOHVGZ-UHFFFAOYSA-N 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- NPMHFMGHDIJHHJ-UHFFFAOYSA-N butyl 4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carboxylate Chemical compound C1CN(C(=O)OCCCC)CCC21N=C(N)C1=C(F)C=CC=C1N2 NPMHFMGHDIJHHJ-UHFFFAOYSA-N 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- PQJLAHMCHXZENU-UHFFFAOYSA-N ethyl 2-(4-amino-1,2-dihydroquinazolin-2-yl)pyrrole-1-carboxylate Chemical compound CCOC(=O)N1C=CC=C1C1N=C(N)C2=CC=CC=C2N1 PQJLAHMCHXZENU-UHFFFAOYSA-N 0.000 claims 1
- OTPGYPKYJVVPAC-UHFFFAOYSA-N ethyl 3-(4-amino-5-fluoro-1,2-dihydroquinazolin-2-yl)pyrrole-1-carboxylate Chemical compound CCOC(=O)N1C=CC(C2N=C(N)C3=C(F)C=CC=C3N2)=C1 OTPGYPKYJVVPAC-UHFFFAOYSA-N 0.000 claims 1
- HZNFNPNOLANCRF-UHFFFAOYSA-N ethyl 4-amino-5-hydroxyspiro[1H-quinazoline-2,4'-piperidine]-1'-carboxylate Chemical compound CCOC(=O)N1CCC2(CC1)Nc1cccc(O)c1C(N)=N2 HZNFNPNOLANCRF-UHFFFAOYSA-N 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- KVJOEMOOQPMHPU-UHFFFAOYSA-N methyl 4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-carboxylate Chemical compound C1CN(C(=O)OC)CCC21N=C(N)C1=CC=CC=C1N2 KVJOEMOOQPMHPU-UHFFFAOYSA-N 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- QUEZQVVHMOJXGT-UHFFFAOYSA-N propan-2-yl 4-aminospiro[1H-quinazoline-2,4'-piperidine]-1'-carboxylate Chemical compound NC1=NC2(NC3=CC=CC=C13)CCN(CC2)C(=O)OC(C)C QUEZQVVHMOJXGT-UHFFFAOYSA-N 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- YAGBUQONHWCOLW-UHFFFAOYSA-N spiro[1h-quinazoline-2,1'-cyclopentane]-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC21CCCC2 YAGBUQONHWCOLW-UHFFFAOYSA-N 0.000 claims 1
- YSIFOLULMFTZKL-UHFFFAOYSA-N spiro[1h-quinazoline-2,4'-piperidine]-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC21CCNCC2 YSIFOLULMFTZKL-UHFFFAOYSA-N 0.000 claims 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 abstract description 11
- 206010061218 Inflammation Diseases 0.000 abstract description 9
- 238000011260 co-administration Methods 0.000 abstract description 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 abstract 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 1
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 34
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 34
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 10
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 10
- 239000000679 carrageenan Substances 0.000 description 10
- 235000010418 carrageenan Nutrition 0.000 description 10
- 229920001525 carrageenan Polymers 0.000 description 10
- 229940113118 carrageenan Drugs 0.000 description 10
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 10
- 206010003246 arthritis Diseases 0.000 description 7
- 210000003414 extremity Anatomy 0.000 description 7
- 150000003180 prostaglandins Chemical class 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000004968 inflammatory condition Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 4
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 4
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 4
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000004962 physiological condition Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101000998969 Homo sapiens Inositol-3-phosphate synthase 1 Proteins 0.000 description 3
- 102100036881 Inositol-3-phosphate synthase 1 Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014987 limb edema Diseases 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 229940124638 COX inhibitor Drugs 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 1
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 1
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N NG-mono-methyl-L-arginine Natural products CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 208000027771 Obstructive airways disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004965 chloroalkyl group Chemical group 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000011554 guinea pig model Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000001129 nonadrenergic effect Effects 0.000 description 1
- 230000002536 noncholinergic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 125000005544 phthalimido group Chemical group 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008409 synovial inflammation Effects 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9802333A SE9802333D0 (sv) | 1998-06-29 | 1998-06-29 | Novel combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CZ20004896A3 true CZ20004896A3 (en) | 2001-06-13 |
Family
ID=20411898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ20004896A CZ20004896A3 (en) | 1998-06-29 | 1999-06-23 | Pharmaceutical preparation containing inhibitor COX-2 and inhibitor iNOS |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6248745B1 (Direct) |
| EP (1) | EP1100505A1 (Direct) |
| JP (1) | JP2002519324A (Direct) |
| KR (1) | KR20010053252A (Direct) |
| CN (1) | CN1313769A (Direct) |
| AU (1) | AU4944799A (Direct) |
| BR (1) | BR9911666A (Direct) |
| CA (1) | CA2334515A1 (Direct) |
| CZ (1) | CZ20004896A3 (Direct) |
| EE (1) | EE200000766A (Direct) |
| ID (1) | ID27394A (Direct) |
| IL (1) | IL140022A0 (Direct) |
| IN (1) | IN2000MU00721A (Direct) |
| IS (1) | IS5794A (Direct) |
| MX (1) | MXPA00012162A (Direct) |
| NO (1) | NO20006559L (Direct) |
| PL (1) | PL345028A1 (Direct) |
| SE (1) | SE9802333D0 (Direct) |
| SK (1) | SK18482000A3 (Direct) |
| TR (1) | TR200003808T2 (Direct) |
| WO (1) | WO2000000200A1 (Direct) |
| ZA (1) | ZA200007076B (Direct) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1376146B (zh) * | 1999-12-08 | 2011-04-06 | 法马西亚公司 | 提高了生物利用率的雪列柯西的固态形式 |
| AP2002002582A0 (en) | 1999-12-23 | 2002-09-30 | Nitromed Inc | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| WO2002060378A2 (en) * | 2000-12-21 | 2002-08-08 | Nitromed, Inc. | Substituted aryl compounds as cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| US7012098B2 (en) * | 2001-03-23 | 2006-03-14 | Pharmacia Corporation | Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers |
| KR20040083478A (ko) * | 2002-01-07 | 2004-10-02 | 파마시아 코포레이션 | 시클로옥시게나제-2 선택성 억제제 및 아스피린의조합물을 이용한 통증, 염증 및 염증-관련 장애의 치료 |
| US7220749B2 (en) | 2002-06-11 | 2007-05-22 | Nitromed, Inc. | Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| US20040077691A1 (en) * | 2002-06-21 | 2004-04-22 | Medinox, Inc. | Hydroxamate derivatives of non-steroidal anti-inflammatory drugs |
| WO2004004648A2 (en) | 2002-07-03 | 2004-01-15 | Nitromed, Inc. | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| WO2004010945A2 (en) | 2002-07-29 | 2004-02-05 | Nitromed, Inc. | Cyclooxygenase- 2 selective inhibitors, compositions and methods of use |
| WO2004019986A1 (en) * | 2002-08-29 | 2004-03-11 | Schering Aktiengesellschaft | Methods of treating acute respiratory distress syndrome |
| JP4354984B2 (ja) | 2003-05-07 | 2009-10-28 | オステオロジックス エイ／エス | 水溶性ストロンチウム塩を用いる軟骨／骨症状の治療 |
| RU2416603C9 (ru) | 2005-10-25 | 2012-06-20 | Сионоги Энд Ко., Лтд. | Производные аминодигидротиазина |
| JP2007275193A (ja) * | 2006-04-04 | 2007-10-25 | Fujifilm Corp | 光プローブおよび光断層画像化装置 |
| WO2008049376A1 (en) | 2006-10-25 | 2008-05-02 | Huawei Technologies Co., Ltd. | Processing location update request method, network entity, congestion control method and apparatus |
| US20100111858A1 (en) * | 2007-01-19 | 2010-05-06 | Howard Carol P | Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands |
| CN101687827B (zh) | 2007-04-24 | 2014-04-23 | 盐野义制药株式会社 | 环状基团取代的氨基二氢噻嗪衍生物 |
| US8653067B2 (en) | 2007-04-24 | 2014-02-18 | Shionogi & Co., Ltd. | Pharmaceutical composition for treating Alzheimer's disease |
| WO2009120186A1 (en) * | 2008-03-24 | 2009-10-01 | Carolus Therapeutics, Inc. | Methods and compositions for treating atherosclerosis and related conditions |
| NZ589590A (en) | 2008-06-13 | 2012-05-25 | Shionogi & Co | Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity |
| JPWO2010047372A1 (ja) | 2008-10-22 | 2012-03-22 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体 |
| US8453441B2 (en) | 2008-11-06 | 2013-06-04 | Purdue Research Foundation | System and method for pump-controlled cylinder cushioning |
| MY145791A (en) * | 2009-05-25 | 2012-04-30 | Liang Woon San | A method for producing a nutraceutical composition and the nutraceutical produced by the method |
| WO2011071135A1 (ja) | 2009-12-11 | 2011-06-16 | 塩野義製薬株式会社 | オキサジン誘導体 |
| JPWO2011077726A1 (ja) * | 2009-12-24 | 2013-05-02 | 塩野義製薬株式会社 | ４−アミノ−１，３−チアジンまたはオキサジン誘導体 |
| EP2524023A1 (en) | 2010-01-13 | 2012-11-21 | Basf Se | Novel mannanase variants |
| EP2545181B1 (en) | 2010-03-12 | 2014-11-12 | Council Of Scientific & Industrial Research | Process for the production of violacein and its derivative deoxyviolacein containing bioactive pigment from chromobacterium sp. (mtcc 5522) |
| DE102010030500A1 (de) | 2010-06-24 | 2011-12-29 | Heliatek Gmbh | Verdampfbares organisch halbleitendes Material und dessen Verwendung in einem optoelektronischen Bauelement |
| AU2011321427A1 (en) | 2010-10-29 | 2013-05-02 | Shionogi & Co., Ltd. | Naphthyridine derivative |
| WO2012057247A1 (ja) | 2010-10-29 | 2012-05-03 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
| DE102011018604A1 (de) | 2011-04-25 | 2014-02-13 | Michael Friebe | Medikamenteninfusor für die Anwendung in stark magnetischen Umgebungen |
| US8883779B2 (en) | 2011-04-26 | 2014-11-11 | Shinogi & Co., Ltd. | Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them |
| EP2713937A1 (de) | 2011-06-01 | 2014-04-09 | Josef Schweiger | Verbundkrone/verbundbrücke und verfahren zu deren herstellung |
| BR112014008152A2 (pt) | 2011-10-07 | 2017-04-18 | Lonza Ag | método para produção de uma proteina de interesse cultivando uma linhagem celular eucariótica recombinante compreendendo uma construção de expressão compreendendo um promotor regulável e uma molécula de ácido nucleico que codifica uma poi sob o controle transcricional de tal promotor |
| DE102012201426A1 (de) | 2012-02-01 | 2013-08-01 | Leibniz-Institut Für Polymerforschung Dresden E.V. | Verfahren zum verbinden von kunststoffen und verfahren zum lösen einer verbindung im kunststoffverbund und kunststoffverbund |
| DE102012007141A1 (de) | 2012-04-10 | 2013-10-10 | Bernhard Spindler | Jalousierbarer Rollladenpanzer |
| DE102012106428A1 (de) | 2012-07-17 | 2014-01-23 | Reha Technology GmbH | Vorrichtung zur therapeutischen Behandlung, System zur gerätegestützten Lokomotionstherapie und Verfahren zur Steuerung der Vorrichtung |
| WO2014024034A1 (es) | 2012-08-08 | 2014-02-13 | Choque Alberto Pati | Compostaje de residuos sólidos, liquidos y lodos biodegradables mediante humus de lombriz (eisenia foetida y especies similares) y mezclas de humus de lombriz y material estomacal con alto contenido de microrganismos |
| DE102012214452B4 (de) | 2012-08-14 | 2019-08-01 | Henkel Ag & Co. Kgaa | Vorrichtung zum Auftragen einer fadenförmigen Masse |
| DE102012016116A1 (de) | 2012-08-15 | 2014-02-20 | Josip Fellner | 360° Bag ln Box Spendersystem |
| DE102012214554A1 (de) | 2012-08-16 | 2014-02-20 | Robert Bosch Gmbh | Verfahren zur Überführung von Batterien in einen entladenen Zustand, Batteriemanagementsystem, Inverter, System zur Erzeugung einer Wechselspannung, Ladestromquelle und Kraftfahrzeug |
| DE102012108153A1 (de) | 2012-09-03 | 2014-03-06 | Ludwig-Maximilians-Universität München | Rohling und Verfahren zur Herstellung einer Dentalrestauration durch substraktive Bearbeitung |
| WO2014065434A1 (en) | 2012-10-24 | 2014-05-01 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity |
| DE102012112186A1 (de) | 2012-12-12 | 2014-06-26 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Materialverbund, Verfahren zu dessen Herstellung, daraus hergestelltes System und Anwendung desselben |
| WO2014135249A2 (de) | 2013-02-15 | 2014-09-12 | Jochen Mertens | Mixer mit massnahmen zur reduzierung des eintrages von luftsauerstoff in den mixer-inhalt |
| DE102013101712B4 (de) | 2013-02-21 | 2020-05-28 | Heliatek Gmbh | Photoaktives organisches Material für optoelektronische Bauelemente |
| DE102013101713B4 (de) | 2013-02-21 | 2020-10-01 | Heliatek Gmbh | Photoaktives, organisches Material für optoelektronische Bauelemente |
| DE102013102366A1 (de) | 2013-03-10 | 2014-09-11 | Informium Ag | Vorrichtungen zur Herstellung und zum Auslesen eines Identifikationsmerkmals mit integriertem Kopierschutz |
| DE102013102365A1 (de) | 2013-03-10 | 2014-09-11 | Informium Ag | Identifikationsmerkmal mit integriertem Kopierschutz |
| DE102013102364A1 (de) | 2013-03-10 | 2014-09-11 | Informium Ag | Verfahren zur Herstellung eines Identifikationsmerkmals mit integriertem Kopierschutz |
| DE102013004288A1 (de) | 2013-03-13 | 2014-09-18 | Matthias Lietzau | Fahrzeug Verbindungsfolie |
| DE202013002767U1 (de) | 2013-03-22 | 2013-05-28 | Lorenz-Montagesysteme Gmbh | Ausgleichende Seitverbindung von Solarmodulen |
| DE102013005741B3 (de) | 2013-04-05 | 2014-05-22 | IOT - Innovative Oberflächentechnologien GmbH | Vorrichtung zur Inertisierung bei UV-Bestrahlung in offenen Durchlaufanlagen |
| EP2792394B1 (de) | 2013-04-16 | 2016-07-27 | Jörg Beutler | Interaktive Geschwindigkeitssteuerung |
| DE102013104501A1 (de) | 2013-05-02 | 2014-11-06 | B. Braun Avitum Ag | Vorrichtung zur extrakorporalen Blutbehandlung |
| DE102013008359A1 (de) | 2013-05-16 | 2014-11-20 | Sew-Eurodrive Gmbh & Co Kg | Energiespeicher, der aus in Reihe geschalten Energiespeicherzellen aufgebaut ist, und Schaltungsanordnung zur passiven Symmetrierung einer Reihenschaltung von Kondensatoren |
| DE102013008919B4 (de) | 2013-05-24 | 2017-12-07 | Magdeburger Windkraftanlagen GmbH | Rotorsystem für die Energiewandlung von kinetischer Energie in Fluiden und Massenströmen |
| DE202013006258U1 (de) | 2013-07-11 | 2013-10-11 | IMM Ingenieurbüro GmbH | Vorrichtung zum Erzeugen von heizbaren Flächen mit homogener Wärmeverteilung |
| DE102013110693B4 (de) | 2013-09-27 | 2024-04-25 | Heliatek Gmbh | Photoaktives, organisches Material für optoelektronische Bauelemente |
| EP2873807A1 (de) | 2013-11-18 | 2015-05-20 | Siemens Aktiengesellschaft | Abdeckplatte, Laufschaufel, Radscheibe, Bolzen und Gasturbine |
| EP3071392B1 (de) | 2013-11-19 | 2019-09-25 | Fraunhofer Gesellschaft zur Förderung der Angewand | Verfahren zum verbinden von silikongummi mit einem substrat |
| EP2902692B1 (de) | 2013-12-06 | 2017-10-25 | MAGNA STEYR Engineering AG & Co KG | Bauteil eines Tanksystems |
| DE202014100570U1 (de) | 2014-02-10 | 2014-03-10 | Schlaadt Plastics Gmbh | Klappsystem zur Verbindung von Partikelschaumbauteilen mittels eines gegen Verlust gesicherten Steckelements |
| DE102014004280A1 (de) | 2014-03-26 | 2015-10-01 | Florian M. König | Impulssignal-Erzeugungsvorrichtung für Zwecke der autonomen Batterieaufladung oder 120-/230-Volt-Lampenversorgung |
| DE202014003299U1 (de) | 2014-04-14 | 2014-08-25 | Antje Koss | Stollenschuh mit Wechselstollensystem |
| DE202014004532U1 (de) | 2014-05-28 | 2014-08-05 | Hans-Dieter Cornelius | Hygienevorlage |
| DE102015214641B4 (de) | 2014-11-10 | 2024-10-24 | Hermann Roth | Zusammensetzung mit Säure und Isochinolinalkaloid |
| DE102014017938A1 (de) | 2014-12-05 | 2016-06-09 | Florian M. König | Trichter-turbinenartige Vorrichtung mit elektromagnetischer Rotationssteuerung von Flüssigkeits-Mischvorgängen |
| DE102015000003A1 (de) | 2015-01-02 | 2016-07-07 | Solukon Ingenieure GbR (vertretungsberechtigte Gesellschafter: Andreas Hartmann, 86391 Stadtbergen und Dominik Schmid, 86165 Augsburg) | Baubehälter für Produktionsanlagen zur Herstellung von Bauteilen in Schichtbauverfahren |
| DE102015008129A1 (de) | 2015-01-22 | 2016-07-28 | Liebherr-Hausgeräte Lienz Gmbh | Verfahren zur Bestimmung der Dämmeigenschaft einer Wandung eines wärmeisolierten Behältnisses |
| DE102015000887A1 (de) | 2015-01-23 | 2016-07-28 | Arnulf Deinzer | Zahnreinigungsgerät mit ausfahrbaren Borsten |
| DE102015015877A1 (de) | 2015-12-09 | 2017-06-14 | Bayerisches Zentrum für angewandte Energieforschung, e.V. (ZAE Bayern) | Optisch schaltendes Element |
| DE102016006696A1 (de) | 2016-05-27 | 2017-11-30 | Christoph Jaeger | Flugautosystem |
| DE202016004226U1 (de) | 2016-07-06 | 2016-11-11 | Helmut Senkel | Schienensystem mit verfahrbaren Verbrauchern |
| CN106279585A (zh) * | 2016-08-26 | 2017-01-04 | 宁波圣达精工智能科技有限公司 | 一种阻燃智能密集书架的制备方法 |
| CN108832306B (zh) * | 2018-06-13 | 2023-11-03 | 中国科学院国家天文台 | 一种fast反射面中心孔柔性封堵结构 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5883102A (en) * | 1995-10-17 | 1999-03-16 | Astra Pharmaceuticals Limited | Pharmaceutically active compounds |
-
1998
- 1998-06-29 SE SE9802333A patent/SE9802333D0/xx unknown
-
1999
- 1999-06-23 IL IL14002299A patent/IL140022A0/xx unknown
- 1999-06-23 CN CN99810007A patent/CN1313769A/zh active Pending
- 1999-06-23 EE EEP200000766A patent/EE200000766A/xx unknown
- 1999-06-23 ID IDW20002691A patent/ID27394A/id unknown
- 1999-06-23 BR BR9911666-9A patent/BR9911666A/pt not_active Application Discontinuation
- 1999-06-23 CZ CZ20004896A patent/CZ20004896A3/cs unknown
- 1999-06-23 KR KR1020007014933A patent/KR20010053252A/ko not_active Withdrawn
- 1999-06-23 TR TR2000/03808T patent/TR200003808T2/xx unknown
- 1999-06-23 US US09/380,379 patent/US6248745B1/en not_active Expired - Fee Related
- 1999-06-23 SK SK1848-2000A patent/SK18482000A3/sk unknown
- 1999-06-23 MX MXPA00012162 patent/MXPA00012162A/es unknown
- 1999-06-23 EP EP99933384A patent/EP1100505A1/en not_active Withdrawn
- 1999-06-23 AU AU49447/99A patent/AU4944799A/en not_active Abandoned
- 1999-06-23 JP JP2000556785A patent/JP2002519324A/ja active Pending
- 1999-06-23 PL PL99345028A patent/PL345028A1/xx not_active Application Discontinuation
- 1999-06-23 CA CA002334515A patent/CA2334515A1/en not_active Abandoned
- 1999-06-23 WO PCT/SE1999/001144 patent/WO2000000200A1/en not_active Ceased
-
2000
- 2000-08-01 IN IN721MU2000 patent/IN2000MU00721A/en unknown
- 2000-11-30 ZA ZA200007076A patent/ZA200007076B/en unknown
- 2000-12-21 NO NO20006559A patent/NO20006559L/no not_active Application Discontinuation
- 2000-12-27 IS IS5794A patent/IS5794A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1100505A1 (en) | 2001-05-23 |
| ID27394A (id) | 2001-04-05 |
| MXPA00012162A (es) | 2001-05-01 |
| PL345028A1 (en) | 2001-11-19 |
| WO2000000200A1 (en) | 2000-01-06 |
| IN2000MU00721A (Direct) | 2005-03-18 |
| SK18482000A3 (sk) | 2001-07-10 |
| JP2002519324A (ja) | 2002-07-02 |
| IL140022A0 (en) | 2002-02-10 |
| CN1313769A (zh) | 2001-09-19 |
| US6248745B1 (en) | 2001-06-19 |
| IS5794A (is) | 2000-12-27 |
| EE200000766A (et) | 2002-06-17 |
| NO20006559D0 (no) | 2000-12-21 |
| CA2334515A1 (en) | 2000-01-06 |
| NO20006559L (no) | 2001-02-28 |
| BR9911666A (pt) | 2001-03-20 |
| TR200003808T2 (tr) | 2001-06-21 |
| KR20010053252A (ko) | 2001-06-25 |
| ZA200007076B (en) | 2002-02-28 |
| SE9802333D0 (sv) | 1998-06-29 |
| AU4944799A (en) | 2000-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ20004896A3 (en) | Pharmaceutical preparation containing inhibitor COX-2 and inhibitor iNOS | |
| CZ20001272A3 (cs) | Nová kombinace | |
| JP6532878B2 (ja) | 組合せ医薬 | |
| AU715380B2 (en) | Pyrazolopyrimidines for treatment of neuronal and other disorders | |
| AP869A (en) | 2,3-Substituted indole compounds as anti-inflammatory and analgesic agents. | |
| DE69936150T2 (de) | Indomethacin-amidderivate zur antiangiogenen und/oder antitumorigen verwendung | |
| CN102850324A (zh) | 吲哚化合物 | |
| KR20020018201A (ko) | 결장 폴립 및 결장직장암의 치료 또는 억제용엔에스에이아이디 및 이지에프알 키나제 억제제 함유 조성물 | |
| JP2013107893A (ja) | 神経線維腫症の処置のためのピリミジルアミノベンズアミド誘導体 | |
| WO2014170873A1 (en) | Compounds with a sirtuin inhibiting activity | |
| KR20220035143A (ko) | 사이클릭 디옥시리보뉴클레오티드 화합물 | |
| CN101171013A (zh) | 嘧啶基氨基苯甲酰胺衍生物用于治疗全身性肥大细胞增多症的应用 | |
| KR20080044277A (ko) | 유기 화합물의 조합물 | |
| JP2006502991A (ja) | マトリックスメタロプロテイナーゼ−１３のアロステリックアルキン阻害剤とセレコキシブまたはバルデコキシブではないシクロオキシゲナーゼ−２の選択的阻害剤との組合せ物 | |
| US4333945A (en) | Thiazoline and imidazoline derivatives useful as minor tranquilizers | |
| JP2009534307A (ja) | 特定の耐性腫瘍の治療のためのキナーゼ阻害剤の使用 | |
| HK1179971A (en) | Indole compounds | |
| AU2009209152A2 (en) | A method of administering a PDE3 inhibitor via titration for the treatment of peripheral arterial disease |